摘要
鼠双微体4(MDM4)作为MDM家族中的一员,是一个由p53负调节的新兴的重要致癌基因。肿瘤抑制蛋白p53在细胞周期停滞、细胞凋亡与平衡中起着至关重要的作用。据报道,在众多的人类癌症,包括血液系统恶性肿瘤已发现p53频繁失活现象。MDM4,新发现的p53蛋白调节器,经常在各种实体肿瘤如皮肤黑色素瘤,视网膜母细胞瘤和血液系统恶性肿瘤(慢性淋巴细胞白血病,急性髓细胞白血病和套细胞淋巴瘤)中放大。多数证据表明, MDM4过度表达与肿瘤发展和预后不良相关,肿瘤发展和预后不良可通过敲除MDM4的表达或恢复p53功能逆转,并支持未来MDM4特异性疗法设计的基本原理。本文讨论并着重运用MDM4作为一种新的生物标志物以及血液系统恶性肿瘤的治疗目标。
关键词: 生物标志物,血液系统恶性肿瘤,MDM2,MDM4,p53,治疗方法。
图形摘要
Current Cancer Drug Targets
Title:Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Volume: 15 Issue: 9
Author(s): Lei Cao, Lei Fan and Jian-Yong Li
Affiliation:
关键词: 生物标志物,血液系统恶性肿瘤,MDM2,MDM4,p53,治疗方法。
摘要: Mouse double minute 4 (MDM4) as a member of MDM family, is an oncogene emerging as an imperative negative regulator of p53. Tumor suppressor protein p53 plays a crucial role in cell cycle arrest, apoptosis and homeostasis. It has been reported that frequent inactivation of p53 was observed in numerous human cancers including hematologic malignancies. MDM4, the newly discovered modulator of p53 protein, is frequently amplified in various solid tumors such as cutaneous melanoma, retinoblastoma and hematological malignances such as chronic lymphocytic leukemia, acute myeloid leukemia and mantle cell lymphoma. Multiple evidences implicate that over-expression of MDM4 is associated with tumor progression and poor prognosis which can be reversed by knockdown of MDM4 expression or restoration of p53 function, and support the rationale for the design of future MDM4-specific therapeutics. This article discusses and focuses on using MDM4 as a novel biomarker as well as a therapeutic target for hematologic malignancies.
Export Options
About this article
Cite this article as:
Lei Cao, Lei Fan and Jian-Yong Li , Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies, Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/156800961509151110124616
DOI https://dx.doi.org/10.2174/156800961509151110124616 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Case of Subcutaneous Phaeohyphomycosis Associated with Leprosy
Infectious Disorders - Drug Targets Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation
Medicinal Chemistry Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Synthesis of 2-(Bis (2-Chloroethyl)Amino)-N-(5-Substitutedphenyl)- 1,3,4- Thiadiazol-2-Yl)Acetohydrazide And Evaluation of Anticancer Activity
Current Bioactive Compounds Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Population Studies of Association Between Lithium and Risk of Neurodegenerative Disorders
Current Alzheimer Research Basis for Resistance to Imatinib in 16 BCR-ABL Mutants as Determined Using Molecular Dynamics
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Peptides Against Autoimmune Neurodegeneration
Current Medicinal Chemistry Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials 1,3,4-Oxadiazole Derivatives as Potential Biological Agents
Mini-Reviews in Medicinal Chemistry Molecular Mechanism of Deguelin in Anti-tumor Effect
Current Pharmaceutical Analysis All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews